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Fig. 1. Decision tree for urokinase therapy. 
$200 per patient, logic dictates that in time the bleeding 
complications should be less with a lesser dose ofurokinase. 
If that lessening occurs, then this cost analysis becomes even 
more practical. 
In future TOPAS articles, I would encourage the 
authors to include costs or charges, or even a decision 
analysis, so that we may all have more data to examine 
urokinase therapy in this age of cost containment. 
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Reply 
To the Editors: 
Dr. Weiland has brought forth some interesting com- 
ments with regard to an economic analysis of the TOPAS 
phase I data. His principles are instructive in reiterating the 
necessity of a rational decision-tree analysis for cost-benefit 
assessment. Dr. Weiland's analysis, however, uses only 
bleeding complications a the measure with which to gauge 
success or failure of the procedure. Clearly, amputation and 
patient mortality rates overshadow bleeding as the most 
appropriate primary endpoints of success. 
The 4000 IU/min uroldnase dose was chosen by the 
investigators a the most appropriate dose to continue phase 
II after a review of all the primary and secondary endpoints 
available after a short period of follow-up. Economic 
outcome was not considered in this decision. Nevertheless, 
the lack of a difference in the length of hospital stay, 
concurrent with trends toward improved 1-year amputa- 
tion-free survival rates in the 4000 IU/min group 
(p = 0.07) suggests that the investigators made an appro- 
priate decision in choosing the intermediate dose. A formal 
cost-benefit analysis is now underway, and the investigators 
hope to have the opportunity to report his data in the near 
future. 
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